OnKure Therapeutics
OKUR
61 hedge funds and large institutions have $45.4M invested in OnKure Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 18 closing their positions.
5,014% more call options, than puts
Call options by funds: $358K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more capital invested
Capital invested by funds: $40.4M → $45.4M (+$4.95M)
6.25% more ownership
Funds ownership: 75.9% → 82.15% (+6.2%)
10% less funds holding
Funds holding: 68 → 61 (-7)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$2.66M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.42M |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
+$667K |
| 4 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$654K |
| 5 |
Renaissance Technologies
New York
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$674K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$549K |
| 3 |
Millennium Management
New York
|
-$254K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$191K |
| 5 |
VPC
Vestal Point Capital
New York
|
-$173K |
OKUR Hedge Fund Activity: Q1 2024 in Review
61 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2024, worth a combined $45.4M — up 12% from $40.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of OKUR and 11 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 14 added.
The largest buyer was Highbridge Capital Management, adding an estimated $2.66M. The largest seller was Ikarian Capital, exiting entirely with an estimated $674K sold.
- 61 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2024, down from 68 in Q4 2023.
- Funds reported $45.4M of OnKure Therapeutics stock for Q1 2024, up 12% quarter-over-quarter.
- 11 funds opened new OnKure Therapeutics positions in Q1 2024 and 18 closed out, a net change of -7 holders.
- The largest OnKure Therapeutics buyer in Q1 2024 was Highbridge Capital Management, an estimated $2.66M added.
- The largest OnKure Therapeutics seller in Q1 2024 was Ikarian Capital, an estimated $674K sold.
Based on aggregated 13F filings for Q1 2024.